Neurocrine Biosciences, Inc. (NBIX) financial statements and ratios from SEC XBRL: revenue $2.86B (TTM), net margin 16.7%, revenue growth 39.5% YoY, P/E 22.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.86B |
| Net Margin | 16.7% |
| Revenue Growth (YoY) | 39.5% |
| EPS Growth (YoY) | 31.2% |
| FCF Growth (YoY) | 43.7% |
| P/E Ratio | 22.0 |
| EV / EBITDA | 18.5 |
| Price / Book | 4.21 |
| Price / Sales | 4.61 |
| FCF Yield | 5.6% |
| DCF Value (model) | $99.79 |
| DCF Upside vs Price | -34.7% |
| Altman Z-Score | 8.34 (safe) |
| Sector P/E (Healthcare) | 21.6 |
NBIX overview · NBIX earnings · NBIX KPIs · NBIX investor relations · NBIX ownership · NBIX peers · NBIX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.